GALVmed aims to make a significant contribution towards transformational change in the small-scale livestock health landscape by developing a portfolio of high impact products and initiating a range of private sector market initiatives operating at scale in the smallholder sector.
About usThis comprehensive report summarises the accomplishments and milestones that shaped the course of our journey and endeavours in 2023. From product and market development to critical partnerships and regulatory advancements, this report reflects our team’s dedication and collective efforts, contributing to the achievement of GALVmed’s mission. Read it here.
Transformational improvement in the well-being and economic progression of small-scale livestock producers.
We will contribute to the transformation of small-scale livestock producers’ lives by:
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Commercial development
Our work with our partners supports the small-scale livestock producers of the world.
Enabling Environment
An enabling environment that allows for the successful translation of research products to sustainable animal health solutions for small scale livestock producers is essential to achieving GALVmed’s mission.
With a rapidly growing population and demand for animal-derived protein, enabling the veterinary sector to address the diverse needs and challenges of small-scale producers is not only possible, but also critical to Africa’s sustainable development.
The misuse of antibiotics in both human and animal health has created an urgent health emergency globally. The resistance of microbes to antibiotics that are constantly used to combat them makes infections harder to treat, creating an antimicrobial resistance (AMR) crisis directly responsible for up to 1.27 million global human deaths as of 2019.
Understanding how adoption translates into economic and other benefits for SSPs is central to our mission. Monitoring and Evaluation (M&E) gives us a structured way to assess these outcomes.
With a rapidly growing population and demand for animal-derived protein, enabling the veterinary sector to address the diverse needs and challenges of small-scale producers is not only possible, but also critical to Africa’s sustainable development.
The misuse of antibiotics in both human and animal health has created an urgent health emergency globally. The resistance of microbes to antibiotics that are constantly used to combat them makes infections harder to treat, creating an antimicrobial resistance (AMR) crisis directly responsible for up to 1.27 million global human deaths as of 2019.
Understanding how adoption translates into economic and other benefits for SSPs is central to our mission. Monitoring and Evaluation (M&E) gives us a structured way to assess these outcomes.
At GALVmed, Monitoring and Evaluation (M&E) is not an afterthought. It is integrated from the very start of the development of new projects and programmes. This approach ensures that our projects are designed with a clear vision of impact.
As of June 2024, the Mutual Recognition Procedure has been extended to also include registration of veterinary ectoparasiticides.